Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Crispr Therapeutics AG

CRSP
Current price
70.6 USD -0.05 USD (-0.07%)
Last closed 71.51 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 5 453 034 496 USD
Yield for 12 month +39.03 %
Week
Month
Year
CRSP
21.11.2021 - 28.11.2021

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. Address: Baarerstrasse 14, Zug, Switzerland, 6300

Analytics

WallStreet Target Price

87.78 USD

P/E ratio

Dividend Yield

Current Year

+436 000 USD

Last Year

+913 081 000 USD

Current Quarter

Last Quarter

+70 000 000 USD

Current Year

-109 814 000 USD

Last Year

+913 081 000 USD

Current Quarter

-23 422 000 USD

Last Quarter

+25 364 000 USD

Key Figures CRSP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -402 879 008 USD
Operating Margin TTM -249.2 %
PE Ratio
Return On Assets TTM -11.93 %
PEG Ratio
Return On Equity TTM -19.21 %
Wall Street Target Price 87.78 USD
Revenue TTM 170 006 000 USD
Book Value 21.75 USD
Revenue Per Share TTM 2.16 USD
Dividend Share
Quarterly Revenue Growth YOY 44203.8 %
Dividend Yield
Gross Profit TTM -570 697 000 USD
Earnings Share -4.47 USD
Diluted Eps TTM -4.47 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -207.95 %

Dividend Analytics CRSP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CRSP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 333333:100
Payout Ratio
Last Split Date 19.07.2016
Dividend Date

Stock Valuation CRSP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 23.3645
Enterprise Value Revenue 23.2545
Price Sales TTM 32.0755
Enterprise Value EBITDA -8.7366
Price Book MRQ 3.1565

Financials CRSP

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CRSP

For 52 weeks

37.55 USD 76.19 USD
50 Day MA 50.38 USD
Shares Short Prior Month 13 889 941
200 Day MA 52.31 USD
Short Ratio 7.48
Shares Short 16 370 356
Short Percent 20.89 %